publication . Article . Other literature type . 2014

Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice

AiHua Shen; Jae-Hyuck Choi; Seong-Kyu Choe; Raekil Park; Seung Hoon Lee; Hong-Seob So; Chul-Ho Lee; Anzani Karna; Tae Hwan Kwak; Hyang Jeong Jo; ...
Open Access
  • Published: 01 Mar 2014 Journal: Kidney International, volume 85, issue 3, pages 547-560 (issn: 0085-2538, Copyright policy)
  • Publisher: Elsevier BV
Cisplatin is a widely used chemotherapeutic agent for the treatment of various tumors. In addition to its antitumor activity, cisplatin affects normal cells and may induce adverse effects, such as ototoxicity, nephrotoxicity, and neuropathy. Various mechanisms, such as DNA adduct formation, mitochondrial dysfunction, oxidative stress, and inflammatory responses, are critically involved in cisplatin-induced adverse effects. As NAD + is a cofactor for various enzymes associated with cellular homeostasis, we studied the effects of increased NAD + levels by means of NAD(P)H:quinone oxidoreductase 1 (NQO1) activation using a known pharmacological activator (β-lapacho...
free text keywords: Nephrology, cisplatin, NAD+, nephrotoxicity, NQO1, sirtuins, Basic Research, Oxidative stress, medicine.disease_cause, medicine, NAD(P)H Dehydrogenase (Quinone), Cellular homeostasis, Biology, Sirtuin 1, biology.protein, Ototoxicity, medicine.disease, NAD+ kinase, Pharmacology, medicine.drug
71 references, page 1 of 5

Rosenberg, B, Vancamp, L, Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965; 205: 698-699 [PubMed]

Wang, D, Lippard, SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4: 307-320 [PubMed]

Cohen, SM, Lippard, SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001; 67: 93-130 [OpenAIRE] [PubMed]

Arany, I, Safirstein, RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23: 460-464 [PubMed]

Siddik, ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22: 7265-7279 [OpenAIRE] [PubMed]

Pabla, N, Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73: 994-1007 [OpenAIRE] [PubMed]

Kuriakose, GC, Kurup, MG. Evaluation of renoprotective effect of Aphanizomenon flos-aquae on cisplatin-induced renal dysfunction in rats. Ren Fail. 2008; 30: 717-725 [OpenAIRE] [PubMed]

Luke, DR, Vadiei, K, Lopez-Berestein, G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 1992; 7: 1-7 [PubMed]

Ciccarelli, RB, Solomon, MJ, Varshavsky, A. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry. 1985; 24: 7533-7540 [PubMed]

Heiger-Bernays, WJ, Essigmann, JM, Lippard, SJ. Effect of the antitumor drug cis-diamminedichloroplatinum (II) and related platinum complexes on eukaryotic DNA replication. Biochemistry. 1990; 29: 8461-8466 [OpenAIRE] [PubMed]

Zamble, DB, Lippard, SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995; 20: 435-439 [OpenAIRE] [PubMed]

Jamieson, ER, Lippard, SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999; 99: 2467-2498 [OpenAIRE] [PubMed]

Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 1987; 34: 155-166 [PubMed]

Huang, B, Yang, XD, Lamb, A. Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal. 2010; 22: 1282-1290 [OpenAIRE] [PubMed]

Ghizzoni, M, Haisma, HJ, Maarsingh, H. Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation. Drug Discov Today. 2011; 16: 504-511 [OpenAIRE] [PubMed]

71 references, page 1 of 5
Any information missing or wrong?Report an Issue